I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

I am a healthcare professional
(outside the UK and Australia):

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

ARVO 2021

-
10:15 AM
Duration 11mins Virtual
Efficacy, durability, and safety of faricimab▼ in diabetic macular edema (DME): one-year results from the phase 3 YOSEMITE and RHINE trials
Wells JA, Wykoff CC, Willis JR, Haskova Z, Lin H, Silverman D, Adamis AP, Ives J, Abreu F, Basu K, Tadayoni R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:15 AM
Duration 9mins Virtual
Multi-modal Geographic Atrophy Lesion Growth Rate Prediction using Deep Learning
Yang Q, Anegondi N, Steffen V, Rabe C, Ferrara D, Gao S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:15 AM
Duration 10mins Virtual
Automated screening of moderately severe and severe nonproliferative diabetic retinopathy from 7 fields color fundus photographs (7F-CFP) using Deep Learning (DL)
Benmansour F, Yang Q, Damopoulos D, Anegond N, Neubert A, Novosel J, Armendariz B, Ferrara D

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
04:30 PM
Duration 7mins Virtual
Pharmacokinetic profile of the Port Delivery System with ranibizumab▼ (PDS) in the phase 3 Archway trial
Campochiaro P, Gune S, Maia M, Ding HT, Maass K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 6mins Virtual
Prediction of ranibizumab▼ injection frequency in patients with macular edema due to retinal vein occlusion during as-needed dosing period of BRAVO and CRUISE Phase 3 trials
Li Y, Steffen V, Benmansour F, Friesenhahn M, Haskova Z

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 11mins Virtual
Simultaneous Ang-2/VEGF-A inhibition prevents subretinal fibrosis progression in preclinical mouse models of choroidal neovascularization (CNV)
Linder M, Foxton R, Uhles S, Revelant F, Lazendic M, Canonica J, Garcia Garrido M, Westenskow P

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 5mins Virtual
Prediction of best-corrected visual acuity (BCVA) from color fundus photography (CFP) using deep learning (DL)
Kawczynski M, Anegondi N, Yang Q, Willis J, Bengtsson T, Gao S, Dai J

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
02:45 PM
Duration 7mins Virtual
The Port Delivery System with ranibizumab (PDS)—a new paradigm for long-acting retinal drug delivery
Stewart J, Tam T, Horvath J, Rea J, Barteselli G, Ranade S

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
11:15 AM
Duration 11mins Virtual
Faricimab▼ in Neovascular Age-Related Macular Degeneration: 1-Year Efficacy, Safety, and Durability in the Phase 3 TENAYA and LUCERNE Trials
Khanani A, Heier J, Quezada Ruiz C, Lin H, Silverman D, Brittain C, Ives J, Swaminathan B, Basu K, Wong T

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Duration 11mins Virtual
Characterization of real-world progression from non-proliferative to proliferative diabetic retinopathy in patients with diabetes
Babiuch A, Gale S, Conti T, McLaughlin L, Kalur A, Gan R, Iyer A, Ferrara D, Greenlee T, Spicer G, Muste J, Hopkins J, Singh R

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar
Coming soon